 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug ERYTHROMYCIN: ERYTHROMYCIN can potentially increase the risk of angioedema. This is based on information from the FDAHandler, which indicates that ERYTHROMYCIN has been [0m
[34massociated with generalized urticarial reactions that can include angioedema and have required systemic steroid therapy.[0m
[1;34m2[0m[34m. Drug ERYTHROMYCIN ETHYLSUCCINATE: The FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not specifically mention an increased risk of angioedema, but it does list allergic reactions as side effects, [0m
[34mwhich could potentially include angioedema. Therefore, while angioedema is not explicitly listed, it may be a possible side effect within the spectrum of allergic reactions to the drug.[0m
[1;34m3[0m[34m. Drug ERYTHROMYCIN: The final answer to the question [0m[34m"Does ERYTHROMYCIN increase or decrease the risk of angioedema?"[0m[34m is that the ERYTHROMYCIN label does not explicitly mention an increased risk of [0m
[34mangioedema. However, it does report generalized urticarial reactions, which can be associated with angioedema. The degree of risk or causality is not confirmed by the label.[0m
[34m                ---------[0m
[34m                Does the erythromycin category of drugs increase the risk of[0m
[34m                angioedema, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the erythromycin category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 states that ERYTHROMYCIN can potentially increase the risk of angioedema, based on FDAHandler information indicating an association with generalized urticarial reactions that can [0m
[32minclude angioedema."[0m[32m,[0m
[32m      [0m[32m"Passage 2 indicates that while the FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not specifically mention an increased risk of angioedema, it lists allergic reactions as side effects, which [0m
[32mcould potentially include angioedema."[0m[32m,[0m
[32m      [0m[32m"Passage 3 reiterates that the ERYTHROMYCIN label does not explicitly mention an increased risk of angioedema but does report generalized urticarial reactions, which can be associated with [0m
[32mangioedema."[0m[32m,[0m
[32m      [0m[32m"The information provided suggests that there is a potential for erythromycin and its derivatives to increase the risk of angioedema, although the degree of risk or causality is not confirmed by[0m
[32mthe labels."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The erythromycin category of drugs potentially increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the erythromycin category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 states that ERYTHROMYCIN can potentially increase the risk of angioedema, based on FDAHandler information indicating an association with generalized urticarial reactions that can [0m
[34minclude angioedema."[0m[34m,[0m
[34m      [0m[34m"Passage 2 indicates that while the FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not specifically mention an increased risk of angioedema, it lists allergic reactions as side effects, which [0m
[34mcould potentially include angioedema."[0m[34m,[0m
[34m      [0m[34m"Passage 3 reiterates that the ERYTHROMYCIN label does not explicitly mention an increased risk of angioedema but does report generalized urticarial reactions, which can be associated with [0m
[34mangioedema."[0m[34m,[0m
[34m      [0m[34m"The information provided suggests that there is a potential for erythromycin and its derivatives to increase the risk of angioedema, although the degree of risk or causality is not confirmed by[0m
[34mthe labels."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The erythromycin category of drugs potentially increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the erythromycin category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m states that ERYTHROMYCIN can potentially increase the risk of angioedema, based on FDAHandler information indicating an association with generalized urticarial reactions that can [0m
[31minclude angioedema.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m indicates that while the FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not specifically mention an increased risk of angioedema, it lists allergic reactions as side effects, which could [0m
[31mpotentially include angioedema.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m reiterates that the ERYTHROMYCIN label does not explicitly mention an increased risk of angioedema but does report generalized urticarial reactions, which can be associated with [0m
[31mangioedema.[0m
[1;31m4[0m[31m. The information provided suggests that there is a potential for erythromycin and its derivatives to increase the risk of angioedema, although the degree of risk or causality is not confirmed by the[0m
[31mlabels.[0m
[31m        -----[0m
[31m        Final answer: The erythromycin category of drugs potentially increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is generally sound. The user has correctly identified that erythromycin is associated with generalized urticarial reactions, which can include angioedema, and [0m
[32mhas noted that while the labels do not explicitly confirm an increased risk of angioedema, the association with allergic reactions suggests a potential increase in risk. The final answer appropriately[0m
[32mreflects the evidence provided, indicating a potential increase in the risk of angioedema with the use of erythromycin category drugs."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is generally sound. The user has correctly identified that erythromycin is associated with generalized urticarial reactions, which can include angioedema, and [0m
[34mhas noted that while the labels do not explicitly confirm an increased risk of angioedema, the association with allergic reactions suggests a potential increase in risk. The final answer appropriately[0m
[34mreflects the evidence provided, indicating a potential increase in the risk of angioedema with the use of erythromycin category drugs."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is generally sound. The user has correctly identified that erythromycin is associated with generalized urticarial reactions, which can include angioedema, and [0m
[31mhas noted that while the labels do not explicitly confirm an increased risk of angioedema, the association with allergic reactions suggests a potential increase in risk. The final answer appropriately[0m
[31mreflects the evidence provided, indicating a potential increase in the risk of angioedema with the use of erythromycin category drugs.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"increase"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.7[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.1[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"rare"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Erythromycin has been associated with generalized urticarial reactions that can include angioedema, as indicated by the FDAHandler. While the FDA label for erythromycin [0m
[32methylsuccinate does not explicitly mention angioedema, it lists allergic reactions as possible side effects, which could potentially include angioedema. The degree of risk or causality is not [0m
[32mconfirmed by the labels, suggesting a potential but not definitive increase in risk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-erythromycin[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
